Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$65.24

-0.31 (-0.47%)

10:43
10/14/16
10/14
10:43
10/14/16
10:43

Battleground: Analysts diverge on bluebird bio after investor day

Shares of bluebird bio (BLUE) are sliding after Cantor Fitzgerald analyst Elemer Piros downgraded the stock to Sell, citing a lack of catalysts in the near-term as he thinks initial data on improved transduction efficiency in beta-thalassemia and severe sickle cell disease may not become available until 2018. Conversely, his peers at Leerink and SunTrust remain bullish on bluebird bio and the company's outlook. LACK OF CATALYSTS: After attending bluebird's analyst and investor meeting yesterday, October 13, Cantor Fitzgerald's Piros downgraded bluebird bio to Sell from Hold citing a lack of upcoming catalysts, as he does not expect any new data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. While bluebird bio disclosed that all future LentiGlobin trials in transfusion-dependent beta-thalassemia and severe sickle cell disease going forward will use its improved manufacturing process, Piros noted that initial data may not become available until 2018 since those trials are just beginning. Further, the analyst told investors that the lack of catalysts for some time should likely lead to selling pressure on the company's shares. He lowered his price target on the stock to $37 from $42. CLINICAL DEVELOPMENT, REGULATORY PATH DE-RISKED: Conversely, Leerink analyst Michael Schmidt remains bullish on bluebird bio, raising his price target on the shares to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. Additionally, Schmidt told investors that he expects updates from ongoing LentiGlobin trials at the upcoming ASH conference. He reiterated an Outperform rating on the shares. IMPROVED OUTLOOK: In a note of his own, SunTrust analyst Edward Nash was also upbeat on bluebird bio, saying that a higher transduction efficiency in LentiGlobin should lead to improved clinical benefit and, therefore, allow the company to target the entire transfusion-dependent B-thalassemia population. Moreover, additional protocol amendments for sickle cell disease will likely have a positive impact on the clinical outcome, Nash added. He also pointed out that he believes bluebird bio is on track in pursuing FDA and EMA approvals for LentiGlobin. The analyst reiterated a Buy rating and $115 price target on the shares. PRICE ACTION: In morning trading, shares of bluebird bio have dropped 6% to $61.31.

  • 06

    Nov

  • 29

    Nov

BLUE bluebird bio
$65.24

-0.31 (-0.47%)

10/14/16
CANT
10/14/16
DOWNGRADE
Target $37
CANT
Sell
Cantor cuts bluebird bio to Sell with $37 price target
Cantor Fitzgerald analyst Elemer Piros downgraded bluebird bio to Sell from Hold and dropped his price target for the shares to $37 from $42. The biotech focused on developing gene therapies closed yesterday down 31c to $64.24. The analyst sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. Bluebird disclosed yesterday that all future LentiGlobin trials going forward will use its improved manufacturing process, and those trials are just beginning, Piros tells investors in a research note. As such, initial data on improved transduction efficiency may not become available until 2018, the analyst contends. With this year's ASH meeting not a catalyst, Piros expects selling pressure on bluebird shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $80
LEER
Outperform
bluebird bio price target raised to $80 from $67 at Leerink
Leerink analyst Michael Schmidt raised his price target for bluebird bio to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. He reiterates an Outperform rating on the shares.
10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
bluebird bio outlook has improved, says SunTrust
SunTrust analyst Edward Nash believes that the improvement in the transduction efficiency of bluebird's LentiGlobin should enable the company "to target the entire transfusion-dependent B-thalassemia population" for the first time. Nash adds that the changes should also improve LentiGlobin's efficacy in sickle cell. He reiterates a $115 price target and Buy rating on the stock.
10/14/16
10/14/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Sell from Hold at Canaccord with the firm citing the gap between the average free cash flow generation of Shell over the past two decades and the medium-term target. 2. bluebird bio (BLUE) downgraded to Sell from Hold at Cantor with analyst Elemer Piros saying he sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. 3. Fluor (FLR) downgraded to Neutral from Accumulate at Seaport Global with analyst Ryan Cassil citing persistently weaker global macroeconomic trends and expectations for a continuation of weaker project activity in 2017. 4. Boston Beer (SAM) downgraded to Hold from Buy at Berenberg. 5. Estee Lauder (EL) downgraded to Neutral from Overweight at Piper Jaffray after the firm's semi-annual proprietary "Taking Stock With Teens" survey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

, TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

FSLR

First Solar

$48.86

0.32 (0.66%)

IMMU

Immunomedics

$11.64

0.38 (3.37%)

JCP

J.C. Penney

$3.97

-0.18 (-4.34%)

IYR

DJ US Real Estate Index Fund

$81.01

-0.63 (-0.77%)

CHK

Chesapeake

$4.04

-0.01 (-0.25%)

SMH

Market Vectors Semiconductor

$92.60

0.24 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Technical Analysis
Technical View: FedEx trades lower after results and outlook »

Shares were last at $213…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Recommendations
Gemphire Therapeutics analyst commentary  »

Gemphire data support…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FDX

FedEx

$216.00

0.92 (0.43%)

08:42
09/20/17
09/20
08:42
09/20/17
08:42
Recommendations
FedEx analyst commentary  »

FedEx price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:42
09/20/17
09/20
08:42
09/20/17
08:42
Hot Stocks
General Mills says expects FY18 tax rate 'in-line' with FY17 »

Sees FY18 tax rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NVS

Novartis

$85.85

0.74 (0.87%)

08:42
09/20/17
09/20
08:42
09/20/17
08:42
Conference/Events
Novartis has a conference call hosted by JPMorgan »

JPMorgan Analyst Vosser…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 17

    May

BABA

Alibaba

$180.07

0.09 (0.05%)

, AAPL

Apple

$158.73

0.06 (0.04%)

08:40
09/20/17
09/20
08:40
09/20/17
08:40
Conference/Events
Bloomberg to hold a forum »

Global Business Forum is…

BABA

Alibaba

$180.07

0.09 (0.05%)

AAPL

Apple

$158.73

0.06 (0.04%)

MA

MasterCard

$142.49

1.09 (0.77%)

UL

Unilever; also tag UN

$59.14

-0.09 (-0.15%)

PEP

PepsiCo

$114.49

-0.5 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 22

    Oct

CSOD

Cornerstone OnDemand

$39.71

-0.61 (-1.51%)

08:40
09/20/17
09/20
08:40
09/20/17
08:40
Recommendations
Cornerstone OnDemand analyst commentary  »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

08:39
09/20/17
09/20
08:39
09/20/17
08:39
Hot Stocks
General Mills says expects margin headwinds to lessen during remainder of FY18 »

Says remains on track for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GM

General Motors

$38.70

0.11 (0.29%)

08:39
09/20/17
09/20
08:39
09/20/17
08:39
Recommendations
General Motors analyst commentary  »

Citi makes case for GM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGI

Celadon Group

$6.50

-0.05 (-0.76%)

08:38
09/20/17
09/20
08:38
09/20/17
08:38
Hot Stocks
Celadon Group closing its truck driving academy »

Celadon Trucking will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALIOF

Actelion

08:35
09/20/17
09/20
08:35
09/20/17
08:35
Conference/Events
Actelion has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath trends getting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMP

Ameriprise

$141.23

0.37 (0.26%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Hot Stocks
Columbia Threadneedle Investments to acquire Lionstone Investments »

Columbia Threadneedle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Hot Stocks
Meet Group to acquire social dating app LOVOO for $70M in cash »

The Meet Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$130.74

0.21 (0.16%)

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Hot Stocks
Nalco Champion announces price increase for customers in all segments »

Nalco Champion, an Ecolab…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SR

Spire

$75.35

-0.05 (-0.07%)

, MC

Moelis

$41.35

0.6 (1.47%)

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Conference/Events
American Gas Association to hold a forum »

2017 Mini-Forum for the…

SR

Spire

$75.35

-0.05 (-0.07%)

MC

Moelis

$41.35

0.6 (1.47%)

ATO

Atmos Energy

$85.93

-0.57 (-0.66%)

CPK

Chesapeake Utilities

$77.40

-1.65 (-2.09%)

ED

Consolidated Edison

$83.41

-0.16 (-0.19%)

ES

Eversource

$61.77

0.08 (0.13%)

NI

NiSource

$26.40

-0.14 (-0.53%)

NWN

Northwest Natural Gas

$65.85

-0.3 (-0.45%)

OGS

ONE Gas

$74.60

-0.11 (-0.15%)

SJI

South Jersey Industries

$35.14

-0.28 (-0.79%)

UGI

UGI Corporation

$47.74

-0.17 (-0.35%)

VVC

Vectren

$66.00

-0.35 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 22

    Oct

  • 31

    Oct

  • 05

    Nov

SCVL

Shoe Carnival

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Upgrade
Shoe Carnival rating change  »

Shoe Carnival upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

KSS

Kohl's

$45.38

0.49 (1.09%)

, AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

08:30
09/20/17
09/20
08:30
09/20/17
08:30
Recommendations
Kohl's, Amazon.com analyst commentary  »

Citi likes Kohl's…

KSS

Kohl's

$45.38

0.49 (1.09%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 09

    Nov

MORE

Monogram Residential Trust

08:30
09/20/17
09/20
08:30
09/20/17
08:30
Options
One option delisting on September 20th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$53.54

-4.26 (-7.37%)

08:29
09/20/17
09/20
08:29
09/20/17
08:29
Recommendations
NuVasive analyst commentary  »

NuVasive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDUS

Radius Health

$33.99

0.28 (0.83%)

08:26
09/20/17
09/20
08:26
09/20/17
08:26
Conference/Events
Radius Health has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.